Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Etopophos

(etoposide phosphate)

Phase 3Small molecule

GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH

Etoposide phosphate is used to treat certain types of cancer, including lung cancer and testicular cancer, by stopping cancer cells from dividing and growing.[1] Etopophos is currently being investigated across 13 indications[3], with its most advanced program in Phase 3.[1]

Etopophos is one of 228 small molecule programs targeting Lymphoma. It is currently in Phase 3.

13

Indications

55

Total Trials

14

Active Trials

227

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaCompleted

Acute Myeloid LeukemiaCompleted

Medulloblastoma RecurrentRecruiting

Hodgkins LymphomaActive, not recruiting

Primitive Neuroectodermal TumorActive, not recruiting

Anaplastic Large Cell LymphomaActive, not recruiting

Recurrent Diffuse Large B-Cell LymphomaRecruiting

Metastatic Ewing SarcomaActive, not recruiting

CNS Embryonal TumorRecruiting

Adult T-Cell Leukemia/lymphomaActive, not recruiting

LymphomaPhase 3

Completed

Acute Myeloid LeukemiaPhase 1

Completed

Medulloblastoma RecurrentPhase 2

Recruiting

Hodgkins LymphomaPreclinical

Active, not recruiting

Primitive Neuroectodermal TumorPreclinical

Active, not recruiting

Anaplastic Large Cell LymphomaPreclinical

Active, not recruiting

Recurrent Diffuse Large B-Cell LymphomaPhase 2

Recruiting

Metastatic Ewing SarcomaPhase 3

Active, not recruiting

CNS Embryonal TumorPhase 1

Recruiting

Adult T-Cell Leukemia/lymphomaPhase 2

Active, not recruiting

Showing 10 of 13 indications

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Etopophos

GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH

Zofran

Cabenuva

Norvir

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Kenalog

BBausch Health Americas, Inc.

Nuvigil

NNuvo Research GmbH

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Decadron

QQuince Therapeutics S.p.A.

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Mediastinal Large B-Cell Lymphoma

NCT04759586

Q2 2027

Phase 2Active, not recruiting

Adult T-Cell Leukemia/lymphoma

NCT03113500

Q2 2029

Phase 3Recruiting

Safety and Efficacy

NCT06188676

Q2 2030

Phase 2Recruiting

Medulloblastoma Recurrent

NCT01356290

Phase 2Active, not recruiting

Rhabdomyosarcoma

NCT01871766

Clinical

Trials by Indication[1]

Lymphoma11 trials

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Completed·UUniversity of California, San Francisco·N/A·NCT00416819·10 enrolled

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT01026220·166 enrolled

Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00002880·53 enrolled

Show 8 more trials

Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00974792·150 enrolled

Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00074178·22 enrolled

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02106988·40 enrolled

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT00302003·287 enrolled

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01132807·164 enrolled

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT02130869·8 enrolled

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Recruiting·UUniversity of Birmingham·Phase 2/3·NCT05991388·210 enrolled

Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma

Completed·WWashington University School of Medicine·Phase 2·NCT01969435·50 enrolled

Neuroblastoma5 trials

Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

Unknown status·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·N/A·NCT00526318·360 enrolled

Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant

Unknown status·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00417053

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma

Completed·CChildren's Oncology Group·Phase 2·NCT00017368·42 enrolled

Show 2 more trials

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Completed·CChildren's Oncology Group·Phase 1·NCT01175356·99 enrolled

Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

Unknown status·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·Phase 3·NCT00410631·642 enrolled

Germ Cell Tumor3 trials

Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors

Completed·MMedical Research Council·Phase 2·NCT00301782·88 enrolled

Combination Chemotherapy and Radiation Therapy in Treating Patients With Germ Cell Tumors in the Brain

Completed·CChildren's Cancer and Leukaemia Group·Phase 3·NCT00293358·500 enrolled

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT02375204·420 enrolled

Acute Lymphoblastic Leukemia3 trials

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01256398·66 enrolled

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00873093·148 enrolled

Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Unknown status·OOhio State University Comprehensive Cancer Center·Phase 2·NCT01005758·180 enrolled

Small Cell Lung Cancer3 trials

Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer

Completed·UUniversity College, London·Phase 3·NCT00433498·846 enrolled

Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer

Unknown status·EEBMT Solid Tumors Working Party·Phase 3·NCT00011921·430 enrolled

Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Withdrawn·CCancer Trials Ireland·Phase 1·NCT01160731

26 more indications

Acute Myeloid Leukemia2 trials

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03983824·48 enrolled

Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01249430·24 enrolled

Carboplatin2 trials

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00074165·17 enrolled

Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

Unknown status·GGOG Foundation·Phase 2·NCT01042522·63 enrolled

Malignant Brain Tumors2 trials

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT00238173·2 enrolled

Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors

Unknown status·OOHSU Knight Cancer Institute·Phase 2·NCT00075387·48 enrolled

Recurrent Diffuse Large B-Cell Lymphoma2 trials

A Phase I Study of Avelumab Plus Utomilumab-Based Combination Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

Completed·CCity of Hope Medical Center·Phase 1·NCT03440567·16 enrolled

A Phase 2 Study of Epcoritamab (Epco) Plus Physician's Choice of Platinum-Containing Chemotherapy Pre-Autologous Hematopoietic Cell Transplantation (AutoHCT) Followed by Post-AutoHCT Epco Consolidation/ Maintenance in Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL)

Recruiting·JJoseph Tuscano·Phase 2·NCT06905509·25 enrolled

Children1 trial

Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL

Completed·UUniversitätsklinikum Hamburg-Eppendorf·Phase 2/3·NCT01228331·745 enrolled

Central Nervous System1 trial

Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00867178·33 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma

Unknown status·UUniversity Hospital Southampton NHS Foundation Trust·N/A·NCT00689845·120 enrolled

Nasopharyngeal Carcinoma1 trial

Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma

Terminated·UUniversity of Florida·Phase 3·NCT02137096·1 enrolled

Relapsed or Refractory Hematologic Malignancies1 trial

Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT01900509·16 enrolled

Side Effects1 trial

Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer

Unknown status·CChildren's Cancer and Leukaemia Group··NCT00897871·60 enrolled

Rhabdomyosarcoma1 trial

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01871766·115 enrolled

Malignant Solid Tumors1 trial

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Terminated·—·Phase 1/2·NCT00788125·7 enrolled

Anaplastic Large Cell Lymphoma1 trial

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Unknown status·EEuropean Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma·N/A·NCT00317408·96 enrolled

Safety and Efficacy1 trial

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Recruiting·NNational Research Center for Hematology, Russia·Phase 3·NCT06188676·100 enrolled

Multiple Myeloma1 trial

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00005792·131 enrolled

Primitive Neuroectodermal Tumor1 trial

Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma

Completed·UUniversitätsklinikum Hamburg-Eppendorf·N/A·NCT00303810·567 enrolled

Chemotherapy1 trial

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT04116359

Ovarian Cancer1 trial

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 1/2·NCT00003064·30 enrolled

Brain Tumors1 trial

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors

Completed·OOHSU Knight Cancer Institute·Phase 1/2·NCT00303849·33 enrolled

Hodgkin Lymphoma1 trial

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT05675410·1,875 enrolled

Medulloblastoma Recurrent1 trial

A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Recruiting·MMedical University of Vienna·Phase 2·NCT01356290·232 enrolled

Mediastinal Large B-cell Lymphoma1 trial

A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT04759586·244 enrolled

Ganglioneuroblastoma1 trial

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Recruiting·CChildren's Oncology Group·Phase 3·NCT03126916·750 enrolled

Adult T-Cell Leukemia/lymphoma1 trial

A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas

Active, not recruiting·CCity of Hope Medical Center·Phase 2·NCT03113500·48 enrolled

Metastatic Ewing Sarcoma1 trial

Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02306161·312 enrolled

CNS Embryonal Tumor1 trial

A Pilot Study of Intrathecal Topotecan and Maintenance Chemotherapy in the Post-consolidation Setting for the Treatment of High-risk Embryonal Central Nervous System Tumours in Children Less Than 6 Years of Age

Recruiting·CC17 Council·Phase 1·NCT06942039·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 55 trial records for etoposide phosphate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — etoposide phosphate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for etoposide phosphate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — German Society for Pediatric Oncology and Hematology GPOH gGmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Topoisomerase II Alpha Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH

Related News